We engineer
and manufacture
platelets.
Inspired by platelet biology to save lives
Thrombocytopenia
(lead program 1)
Developing universal* platelets for treatment in patients with, or at risk of, HLA immune-refractoriness.
Tissue-targeted cargo delivery
(lead program 2)
Using our unique CAR-PLT® technology for shielded delivery of miRNA/siRNA or proteins to specific target tissues.
Regenerative medicine
Using engineered platelets in wound healing, anti-inflammatory and immunomodulating applications.
Culture of therapeutic stem cells
Using platelet lysate produced from our universal platelets to boost cell proliferation.
* engineered to be HLA-null
HemostOD: a swiss-based preclinical company
Founded in 2020, HemostOD is a biotech company based at the EPFL Innovation Park in Lausanne, Switzerland.
We are a preclinical stage company developing applications based on our proprietary platform to engineer and manufacture universal platelets.
A unique & scalable
platelet manufacturing
platform
Immortalization of hematopoietic progenitors (stem) cells from a single donor.
Engineering of cells to introduce custom features, modifying the platelet surface and/or content for controlled release.
Differentiation into a practically unlimited source of megakaryocytes, the platelet progenitor cells.
Ex-vivo generation of platelets in a robust, fast and scalable manufacturing process.
HemostOD cell line
Engineered
HemostOD cell line
Megakaryocytes
Platelets
Partnering opportunities
- Thrombocytopenia,
- Tissue-targeted cargo delivery technology (CAR-PLT®),
- Regenerative medicine,
- Culture of therapeutic stem cells (platelet lysate),
and beyond.
HemostOD receives a FIT Tech Growth loan
HemostOD received the support of the “Fondation pour l’Innovation Technologique” (FIT) in the form of a CHF 500’000 loan: the FIT Tech Growth. The FIT
HemostOD partners with the biggest transfusion service in Switzerland
The Swiss preclinical biotech company HemostOD and Interregional Blood Transfusion SRC, the biggest Swiss blood transfusion services, are pleased to announce their partnership to collaborate
HemostOD enters EIT Health’s Gold Track Programme
HemostOD has been recognized as a promising healthcare company by a jury of experts. The team will now receive tailored support to grow the company.
Partnering with the Swiss Biotech Center
HemostOD partners with the Swiss Biotech Center to pre-industrialize its technology. Thanks to this new partnership HemostOD will benefit from solid expertise and state-of-the-art infrastructure